EMA Application withdrawn: Garenoxacin mesylate — Schering-Plough Europe

View source ↗

Summary

The EMA application for garenoxacin mesylate by Schering-Plough Europe was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis Chronic
• Pneumonia
• Sinusitis
• Skin Diseases Infectious
• Soft Tissue Infections
• Surgical Wound Infection

Drugs mentioned

• garenoxacin mesylate (garenoxacin mesylate)

Snippet

Status: Application withdrawn. Therapeutic area: Surgical Wound Infection;Sinusitis;Skin Diseases, Infectious;Pneumonia;Soft Tissue Infections;Bronchitis, Chronic. MAH: Schering-Plough Europe. Decision date: 31/12/2009